Article ID Journal Published Year Pages File Type
3269744 HPB 2009 6 Pages PDF
Abstract
Bortezomib and gemcitabine demonstrate additive antitumour activity in vitro and in an experimental PaCa model, indicating the potential for clinical PaCa benefits of additional multiagent therapies that will be based upon the bortezomib and gemcitabine combination.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Endocrinology, Diabetes and Metabolism
Preview
Proteasome inhibition enhances antitumour effects of gemcitabine in experimental pancreatic cancer
Authors
, , ,